[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ckd---chronic-kidney-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ckd---chronic-kidney-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,72,100,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100645023","association-between-chronic-kidney-disease-stage-and-circulating-fgf23-cleavage-intensity-in-patients-with-chronic-kidney-disease-100645023",false,"NCT07676526","Association Between Chronic Kidney Disease Stage and Circulating FGF23 Cleavage Intensity in Patients With Chronic Kidney Disease","CLIFF","Inclusion Criteria:\n\n* MRC stage 3a-5 based on the most recent GFR measurement\n* Patient enrolled in or eligible for a social security program\n* Patients who have received informed consent regarding the study and have given their verbal consent to participate\n\nExclusion Criteria:\n\n* Active cancer or a history of cancer in remission for less than 5 years, or a history of cancer in remission for more than 5 years with specific oncological treatment still ongoing.\n* Participation in another study related to treatments for the disease\n* Patients under legal guardianship (legal guardianship or conservatorship)","MALE","55 Years","75 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","This cross-sectional proof-of-concept study aims to investigate the relationship between chronic kidney disease (CKD) severity and circulating FGF23 cleavage intensity estimated by the iFGF23\u002FcFGF23 ratio. Eighty male patients aged 55-75 years with CKD stages 3a to 5 will be included (20 per stage). Blood samples obtained during routine nephrology care will be supplemented by two additional tubes to measure iFGF23, cFGF23, hepcidin, erythropoietin, 1,25-vitamin D and TRAP5b. The primary endpoint is the iFGF23\u002FcFGF23 ratio. Secondary analyses will evaluate the associations between FGF23 forms and renal, hematological, iron metabolism and mineral bone parameters. This study will provide the first human data on FGF23 cleavage alterations across CKD stages and may identify novel biomarkers for anemia and cardiovascular complications.",[27],"CKD - Chronic Kidney Disease",[29,30,31,32,33],"CKD","FGF23","iFGF23\u002FcFGF23 ratio","iron metabolism","anemia","NOT_YET_RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":21},"2026-09",{"date":42,"type":21},"2027-05",{"name":44,"class":45},"Centre Hospitalier Universitaire de Saint Etienne","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100634238","phase-4-efficacy-and-safety-of-triple-therapy-with-dulaglutide-sglt2-inhibitors-and-finerenone-in-chinese-adults-with-type-2-diabetes-and-chronic-kidney-disease-100634238","NCT07537088","Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease","Efficacy and Safety of Dulaglutide, SGLT-2 Inhibitors, and Finerenone Triple Therapy in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease: A Multicenter, Prospective, Randomized Controlled Study","Inclusion Criteria:\n\n* 1.Patients aged ≥18 years with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD)\n* 2.Hemoglobin A1c (HbA1c) 7.0%-11%\n* 3.Urine albumin-to-creatinine ratio (UACR) 300-5000 mg\u002Fg\n* 4.Body mass index (BMI) 21-45 kg\u002Fm²\n* 5.Having received combination therapy with SGLT2 inhibitor and finerenone for 3 months or longer, on the basis of maximum tolerated dose of renin-angiotensin system inhibitor (RASi)\n* 6.Sign the informed consent, understand the procedures and methods of this trial and willing to strictly comply with the clinical trial protocol\n\nExclusion Criteria:\n\n* 1.Pregnant or lactating women, or women of childbearing potential unwilling to use reliable contraception\n* 2.History of definite contraindications or intolerance to glucagon-like peptide-1 receptor agonists (GLP-1RA), SGLT2 inhibitors, or finerenone\n* 3.Type 1 diabetes\n* 4.History of diabetic ketoacidosis (DKA) within the past 6 months\n* 5.Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m²\n* 6.Hospitalization within 30 days prior to screening for acute coronary syndrome (ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, or unstable angina), percutaneous coronary intervention, or cardiac surgery\n* 7.Uncontrolled hypertension, defined as systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg (mean of three supine measurements) during screening\n* 8.Symptomatic hypotension and\u002For systolic blood pressure \\\u003C90 mmHg at screening, or patients judged by the investigator to have hypovolemia\n* 9.Serum potassium \\>5.0 mmol\u002FL at screening\n* 10.Current use or use within 3 months prior to screening of GLP-1 receptor agonists or other mineralocorticoid receptor antagonists (e.g., spironolactone)\n* 11.Patients receiving or with clear clinical indications requiring systemic immunosuppressive therapy (including but not limited to prednisone, cyclosporine, etc.) for other kidney diseases (e.g., primary or secondary glomerulonephritis, lupus nephritis)\n* 12.History of recurrent urinary tract or genital infections (as judged by the investigator)\n* 13.Life expectancy \\\u003C1 year at screening\n* 14.Confirmed malignancy\n* 15.Participation in another clinical trial within 3 months prior to screening\n* 16.Any other condition judged by the investigator as unsuitable for participation in this clinical trial.","ALL","18 Years",{"count":57,"type":21},468,[59],"PHASE4","The purpose of this study is to evaluate whether adding dulaglutide to the combination therapy of Sodium-Glucose Co-Transporter 2 Inhibitors(SGLT2i) and finerenone can provide additional kidney protection and safety for Chinese adults with Type 2 Diabetes Mellitus(T2DM) and Chronic Kidney Disease(CKD). Eligible participants will be adults with T2DM and mild-to-moderate CKD who have been receiving SGLT2 inhibitor plus finerenone for at least 3 months on the basis of maximum tolerated dose of renin-angiotensin system inhibitor (RASi). Participants will be randomly assigned to either continue the original regimen or to receive add-on therapy with dulaglutide.The study will last for 26 weeks, with participants required to attend scheduled visits for efficacy and safety assessments at Week 13 (±1 week) and Week 26 (±1 week, final visit).",[62,27],"T2DM (Type 2 Diabetes Mellitus)","2026-04-17",{"date":65,"type":38},"2026-04-22",{"date":67,"type":21},"2026-05",{"date":69,"type":21},"2027-07",{"name":71,"class":45},"First Affiliated Hospital of Wannan Medical College",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100615302","the-effects-of-dietary-nitrate-in-patients-with-hypertensive-kidney-injury-100615302","NCT07290842","The Effects of Dietary Nitrate in Patients With Hypertensive Kidney Injury","DINO-CKD","Inclusion Criteria:\n\n* Hypertension, treated with a maximum of 2 antihypertensive drugs and unattended office BP \\\u003C 150\u002F95 mmHg at the screening visit, or newly diagnosed without antihypertensive treatment by 24-hour BP or home BP measurement (above 130\u002F80 or 135\u002F85 respectively), and unattended office BP \\\u003C 160\u002F100 mmHg.\n\n  * CKD I-III based on hypertensive kidney injury. Patients, who previously met the criteria for CKD I within the last 5 years, but no longer has proteinuria after relevant treatment, can also be included. Diagnosis of CKD I can be based on eGFR and either urine albumin\u002Fcreatine ration or urine-dipstick test with presence of protein.\n  * Albumin\u002Fcreatinine ratio \\\u003C 500 mg\u002Fg\n  * eGFR \\> 30 ml\u002Fmin\u002F1,73m2\n  * Body Mass Index (BMI) ≤ 35 kg\u002Fm2\n  * Able to adhere to dietary regimen\n  * Fertile women must use safe contraception (oral contraceptive pill, hormonal or copper intrauterine device, vaginal ring, contraceptive implant, transdermal contraceptive patch or contraceptive injections) or abstinence. Excluded from this are postmenopausal woman without menstrual bleeding for at least 12 months before inclusion, surgically sterilized women and women with surgically sterilized partner.\n\nExclusion Criteria:\n\n* • Diagnosis of heart failure, NYHA II-IV\n\n  * Diagnosis of liver failure\n  * Diabetes mellitus (all types)\n  * Current malignant disease (other than non-melanoma skin cancer)\n  * Indicators of other aetiologies of CKD than hypertensive kidney injury, e.g. through kidney biopsy or biochemistry.\n  * Previous kidney transplant recipient\n  * History of stroke or transient cerebral ischemic attack\n  * Current indication of untreated cardiovascular disease, e.g. planned work-up for ischemia.\n  * History of myocardial infarction, apart from non-STEMI more than 1 year prior to the study, if the subject is currently revascularized and relevantly medicated.\n\nOrganic nitrate treatment Diagnosed secondary hypertension other than renal parenchymal hypertension (i.e. renal artery stenosis, primary hyperaldosteronism, low renin hypertension etc.)\n\n* Pregnancy or lactation\n* Alcohol abuse (intake above the recommended guidelines from Danish Health Authorities)\n* Conditions treated with medication that investigator finds may interfere with the effect parameters, and cannot be discontinued during the trial (e.g. atrial fibrillation treated with betablockers)\n* If, according to the investigator's assessment, the participant is considered unsuitable to participate.","70 Years",{"count":81,"type":21},20,[24],"The study aims to study the effects of diatery nitrate in patients with hypertension and hypertensive kidney injury.\n\nThe study is a randomized, placebo-controlled, double-blinded crossover trial. 14-20 patients with hypertension and CKD I-III will be randomized to receive either nitrate or placebo delivered in the form of beetroot juice.\n\nEffect variables will be measured before and after a 2 week treatment. After a washout period of 14 days, the subjects are crossed over to the opposite treatment.\n\nThe study is terminated by measuring effect variables after the second treatment period.",[85,27],"Hypertension",[87,88,89],"nitrate","hypertension","beetroot","RECRUITING","2025-12-17",{"date":93,"type":38},"2025-12-18",{"date":95,"type":38},"2025-12-08",{"date":97,"type":21},"2030-01-01",{"name":99,"class":45},"Gødstrup Hospital",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":46},"100611197","cardiovascular-and-renal-endpoints-with-flozins---an-observational-prospective-study-in-ckd-hfpef-patients-100611197","NCT07237451","Cardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients","CARE FOR CKD H","Inclusion Criteria:\n\n* age\\>18 years;\n* ejection fraction \\> 40;\n* patients with CKD stage 3-4 (eGFR between 15-60 mL\u002Fmin\u002F1.73m2), with iSGLT2 recommendation, diabetic and non-diabetic;\n* age, sex and CKD stage 3 and 4 matched patients without iSGLT2 administration.\n\nExclusion Criteria:\n\n* eGFR\\\u003C 15 mL\u002Fmin\u002F1.73m2 or patients undergoing dialysis;\n* presence of congenital heart disease, decompensated cirrhosis, pregnancy and active malignancies;\n* coronary artery disease (including those with a history of acute coronary syndrome, angina pectoris, or prior coronary angiography or CT angiography demonstrating significant coronary artery lesions);\n* cardiac medical devices, namely metallic joint prostheses, cardiac stent or pacemakers;\n* active systemic infections (due to interference with biomarkers that can give false rise values).",{"count":108,"type":21},200,"OBSERVATIONAL","The main aim of this study is to holistically assess the cardiovascular and renal outcomes in HFpEF CKD patients with and without SGLT2 inhibition, with focus on the endothelial disfunction, MACE and mortality using clinical evaluation, flow mediated dilatation, carotid-femoral pulse wave velocity, intima-media thickness, echocardiographic parameters, NMR metabolomics and a series of novel biomarkers.",[27,112,113,114],"Heart Failure Preserved Ejection Fraction","SGLT2 Inhibitors","Diabetes (DM)",[29,116,117,118,119],"HFpEF","SGTL2 inhibitors","Biomarkers","PWV","2025-11-16",{"date":122,"type":38},"2025-11-19",{"date":124,"type":38},"2025-01-08",{"date":126,"type":21},"2027-12-31",{"name":128,"class":45},"Grigore T. Popa University of Medicine and Pharmacy",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":46},"100601932","phase-4-ganagliflozin-on-the-progression-of-kidney-disease-in-subjects-with-type-2-diabetes-mellitus-and-chronic-kidney-disease-100601932","NCT07116928","Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease","A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease","GLOW-CKD","Inclusion Criteria:\n\n* Male or female individuals aged 18 years and above;\n* Meets the diagnostic criteria for T2DM;\n* Meets the diagnostic criteria for CKD, during the screening period（CKD-EPI Formula）: eGFR ≥ 30 to \\\u003C 60 mL\u002Fmin\u002F1.73m\\^2, and UACR is ≥ 30 to \\\u003C 5000 mg\u002Fg; Or eGFR ≥ 60 to \\\u003C 90 mL\u002Fmin\u002F1.73m\\^2, and UACR is ≥ 300 to \\\u003C 5000 mg\u002Fg ;\n* HbA1c ≥ 6.5% to ≤ 12%;\n* If there are no contraindications or special instructions, all subjects must take a stable dose of ACEi or ARB at least 4 weeks before randomization;\n\nExclusion Criteria:\n\n* Patients with type 1 diabetes or other special types of diabetes;\n* A medical history or clinical evidence indicating that the subjects have other primary kidney diseases and secondary kidney diseases other than type 2 diabetes (including but not limited to lupus nephritis, ANCA-related nephritis);\n* History of kidney transplantation;\n* Blood potassium level \\> 5.5 mmol\u002FL during the screening period.\n* New York Heart Association (NYHA) classification of grade IV during the screening period;\n* Experienced ketoacidosis, myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack (TIA), hospitalization due to heart failure, or hospitalization due to urinary tract infection or acute kidney injury within 12 weeks before the screening period;\n* Receiving ACEi and ARB in combination;\n* Receiving mineralocorticoid receptor antagonists (MRA) or direct renin inhibitors (DRI) within 8 weeks before randomization;\n* Receiving drugs with immunosuppressive effects (such as cyclophosphamide, cyclosporine A, tacrolimus, etc.) or biological agents (rituximab, belimumab, etc.) during the 12 weeks before the screening period;\n* Receiving SGLT-2 inhibitors or GLP-1 receptor agonists within 8 weeks before the screening, or have previously used SGLT-2 inhibitor drugs and discontinued due to poor efficacy.",{"count":138,"type":21},1244,[59],"This study aims to investigate the impact of adding Ganagliflozin tablets to the current background therapy on preventing the progression of kidney disease in subjects with type 2 diabetes and chronic kidney disease. The efficacy and safety will be evaluated by comparing the effects of Ganagliflozin tablets and placebo tablets added to the current background treatment over 120 weeks",[62,27],{"date":143,"type":38},"2025-11-18",{"date":145,"type":21},"2025-11-30",{"date":147,"type":21},"2031-12-30",{"name":149,"class":150},"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","INDUSTRY"]